Locus Biosciences Makes Progress in Gene Editing and Clinical Trials

Locus Biosciences is making significant strides in the field of gene editing and clinical trials. The company has developed a proprietary CRISPR-Cas13 system that has shown promise in treating bacterial infections.

This innovative approach has the potential to revolutionize the way we treat certain diseases. By targeting and eliminating specific bacterial genes, Locus Biosciences' technology may provide a more effective and targeted treatment.

Locus Biosciences is currently conducting clinical trials to test the safety and efficacy of its CRISPR-Cas13 system. The company has received funding to support its research and has established partnerships with major pharmaceutical companies.

The results of these trials will be crucial in determining the future of gene editing as a medical treatment.

Broaden your view: Deferred Compensation Tax Treatment for Employer

Locus Biosciences has secured significant funding to support its CRISPR-enhanced bacteriophage therapy. The company received $23.9 million from the Biomedical Advanced Research and Development Authority (BARDA) to begin a clinical trial of its LBP-EC01 therapy.

For your interest: Couples Therapy Covered

This funding brings the total amount released under a contract with BARDA to $48.9 million. The company initially entered a contract with BARDA in 2020 for up to $85 million to co-fund the development of LBP-EC01.

Locus Biosciences has also signed a historic deal with Janssen Pharmaceuticals, Inc. for the development and manufacturing of CRISPR-Cas3-enhanced bacteriophage products. This agreement includes an initial investment of $20 million and is potentially worth up to $818 million.

The company's foundation was built on CRISPR research conducted by two of its scientific founders at NC State. The university exclusively licensed several patents related to the CRISPR-Cas3 technology Locus for global use.

Locus Biosciences is the world leader in CRISPR-engineered phage therapeutics, a technology that degrades the DNA of target bacteria cells and quickly destroys them. This approach could provide a turning point in the global battle against antibiotic-resistant infections and other microbiome dysbiosis-related conditions.

Take a look at this: Related Companies

Locus Biosciences made significant progress in clinical development, starting with its first patient enrollment in a Phase 1b clinical trial for LBP-EC01 in 2020.

The company successfully completed this trial in 2021, a notable achievement in the development process.

Positive results from Part 1 of a two-part Phase 2 clinical trial of LBP-EC01 were published in The Lancet Infectious Diseases, leading to additional funding of $23.9 million from BARDA to support the second part of the trial.

Take a look at this: Docusign Free Trial Limitations

Building a phage factory is a crucial step in harnessing the power of bacteriophages to fight infections. It involves creating a controlled environment where phages can be produced and stored for later use.

In the laboratory, scientists have successfully built phage factories using E. coli as a host organism. This approach leverages the bacteria's ability to produce high yields of phage particles.

The first phage factory was established at the University of California, San Francisco, where researchers demonstrated the feasibility of large-scale phage production.

The company started its clinical development with a Phase 1b clinical trial for LBP-EC01 in 2020, and it was completed successfully in 2021.

They enrolled their first patient in this trial, marking an important milestone in the development process.

Positive results from Part 1 of a two-part Phase 2 clinical trial of LBP-EC01 were announced, which was a significant breakthrough.

These positive results led to an additional $23.9 million in funding from BARDA to support Part 2 of the Phase 2 clinical trial.

This funding is a testament to the potential of LBP-EC01 and the company's commitment to its development.

For another approach, see: Examples of Positive Risk Taking